A federal appeals court has blocked the mailing of mifepristone, an abortion pill, under the current FDA regulations. The 5th U.S. Circuit Court of Appeals acknowledged that this decision “would, as a practical matter, have a nationwide effect,” suggesting it could create a major ripple effect across the country.
This ruling may restrict access to mifepristone, which is widely used in medication abortions and accounts for a majority of abortions in the U.S. A requirement reinstated by the court means women must now visit a medical professional to obtain a prescription for the drug. This reinstatement of in-person requirements comes after the FDA previously relaxed restrictions during the COVID-19 pandemic.
The court’s order effectively stops mail-order distribution of mifepristone and blocks pharmacy dispensing, reverting to earlier safety protocols. In its ruling, the court criticized the FDA’s handling of safety data, noting that the agency had previously eliminated mandatory reporting of the drug’s adverse effects. The judges deemed it “unreasonable” to relax reporting requirements and then use the lack of data to expand access.
The decision aligns with arguments from states like Louisiana, which suggested that federal policy undermines their authority to regulate abortion. The court stated, “Every abortion facilitated by FDA’s action cancels Louisiana’s ban,” emphasizing the state’s belief that every unborn child should be recognized as a human being from the moment of conception. This reflects a broader trend in the legal realm where state laws clash with federal regulations following the Supreme Court’s reversal of Roe v. Wade.
Pro-life advocates have responded positively. Kristan Hawkins, president of Students for Life, called the decision a long-awaited victory. She expressed hope that the ruling would hold, stating, “We can’t remain the United States of America if abortion-loving states allow criminal enterprises to be set up, breaking the laws of their pro-life neighbors.” Family Research Council President Tony Perkins echoed this sentiment, labeling the ruling “great news for the unborn.” He further indicated that he expects the matter to come before the U.S. Supreme Court soon.
On the other hand, advocates for pro-choice agendas sharply criticized the ruling. New York Attorney General Letitia James described mifepristone as “safe, effective, and essential,” condemning the ruling as “yet another cruel attack on abortion access.” She asserted that restrictions on abortion care equate to restrictions on vital healthcare services.
Furthermore, Judge David C. Joseph had previously cautioned against “government by lawsuit,” suggesting that the ongoing safety review by the FDA, rather than court decisions, should steer long-term policy regarding the drug. This review is crucial as the Department of Health and Human Services and the FDA are currently assessing safety data and adverse events linked to mifepristone.
Louisiana Attorney General Liz Murrill emphasized that the federal policy posed daily “irreparable harm,” suggesting that expanded access reached into jurisdictions with strict state-level abortion laws. The court’s decision may spark a significant appeal to the Supreme Court, bringing renewed attention to the matter of federal authority over abortion drug regulation.
The legal landscape of abortion access is changing, confronting the balance between state and federal powers. With ongoing challenges and debates, the implications of Friday’s ruling could resonate well beyond state lines, affecting countless women and the healthcare providers who support them.
"*" indicates required fields
